XML 39 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Research, Development, and License Agreements - Additional Information (Detail) (USD $)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended
Dec. 31, 2008
Glaxo, Smith, Kline
Project
Jun. 30, 2013
Glaxo, Smith, Kline
Jun. 30, 2012
Glaxo, Smith, Kline
Jun. 30, 2013
Glaxo, Smith, Kline
Jun. 30, 2012
Glaxo, Smith, Kline
Dec. 31, 2011
Glaxo, Smith, Kline
Dec. 31, 2012
Glaxo, Smith, Kline
Jun. 30, 2013
Glaxo, Smith, Kline
Maximum
Dec. 31, 2011
Glaxo, Smith, Kline
Expansion
Jun. 30, 2013
Glaxo, Smith, Kline
Follow-On TLR 7/9 program and other TLR programs
Maximum
Jun. 30, 2013
Glaxo, Smith, Kline
Annual net sales milestones achieved
Maximum
Sep. 30, 2006
Astra Zeneca
Jun. 30, 2013
Astra Zeneca
Jun. 30, 2012
Astra Zeneca
Jun. 30, 2013
Astra Zeneca
Jun. 30, 2012
Astra Zeneca
Dec. 31, 2008
Astra Zeneca
Dec. 31, 2012
Astra Zeneca
Oct. 31, 2011
Amendment
Dec. 31, 2011
Amendment
Dec. 31, 2012
Amendment
Advance the program following completion of Phase 2a
Mar. 31, 2012
Amendment
Advance the program following completion of Phase 2a
Jun. 30, 2013
Amendment
Advance the program following completion of Phase 2a
Jun. 30, 2013
Amendment
Advance the program following completion of Phase 2a
Maximum
Jun. 30, 2012
National Institutes of Health
Autoimmune Disease
May 31, 2012
National Institutes of Health
Rheumatoid Arthiritis
Jul. 31, 2011
National Institutes of Health
Skin Autoimmune Inflammation
Aug. 31, 2010
National Institutes of Health
HBV
Jul. 31, 2010
National Institutes of Health
HPV
Sep. 30, 2008
National Institutes of Health
ISS Technology
Product Information [Line Items]                                                            
Number of programs for research and early clinical development 4                                                          
Potential milestone payment               $ 125,000,000   $ 12,000,000 $ 60,000,000                                      
Collaboration Revenue 10,000,000 357,000 357,000 714,000 714,000             10,000,000 180,000 180,000 360,000 360,000     3,000,000   6,000,000 2,600,000                
Revenue from milestone payment           12,000,000     3,000,000       819,000 1,086,000 1,165,000 1,478,000 4,500,000           20,000,000 100,000,000            
Deferred revenue recognition period   7 years   7 years                 50 months   50 months                              
Deferred revenue   3,500,000   3,500,000     4,200,000           6,500,000   6,500,000     7,700,000                        
Research collaboration and license agreement period                       3 years                                    
Cost of clinical development activities                                       20,000,000                    
Grants receivable                                                 600,000 400,000 600,000 1,100,000 600,000  
Contract agreement period                                                           5 years
Contract awarded to develop technology                                                           $ 17,000,000